General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0QECGQ
ADC Name
algM ADC
Synonyms
algM ADC
   Click to Show/Hide
Organization
Technical University of Darmstadt.
Drug Status
Investigative
Structure
Antibody Name
Masked chicken-derived anti-IgM (aIgM) antibody
 Antibody Info 
Antigen Name
Undisclosed
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
DBCO-PEG4-Val-Cit-PABC
 Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.66
nM
CVCL_0597
Burkitt lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.66 nM
Method Description
Cytotoxic effects of aIgM ADCs were evaluated by exposing IgM+ lymphoma B cells or off-target (IgM-) cells to different ADC concentrations. Cell viability was analyzed 72 h post ADC addition by a colorimetric method using CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). Briefly, cells were seeded (1x104 cells/well) in a 96-well plate with the desired antibody concentrations ranging from 0.014-90 nM in a serial dilution. After 72 h, MTS solution was added to the cells and plate was incubated for 2 h. Absorption was measured at 490 nm using CLARIOstar plus microplate reader (BMG LABTECH). Cell proliferation was normalized to untreated control cell absorption values. The resulting curves were fitted with a variable slope four-parameter fit and EC50s were calculated using GraphPad Prism.

   Click to Show/Hide
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
References
Ref 1 Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting